Novocure Ltd (NVCR) News & Events

$14.640

+0.244 (+1.67%)At close

NVCR News

9.510-01Newsfilter

Novocure to Report Q3 2026 Financial Results on October 29

1.009-02Newsfilter

Novocure to Participate in Upcoming Investor Events

7.507-24NASDAQ.COM

Biotech Stocks Reach 52-Week Highs Following Key Catalysts

9.507-24stocktwits

CSX, Union Pacific, and Novocure Exceed Earnings Expectations

2.007-24NASDAQ.COM

Biotech Stocks Surge with Advanced Biomed Leading Gains

9.507-23stocktwits

NovoCure Reports Record Q2 Performance Amid Challenges

9.507-23seekingalpha

NovoCure Reports Strong Q2 2026 Earnings with Revenue Growth

9.507-23seekingalpha

NovoCure Shares Surge 25% After Beating Q2 Earnings and Raising Revenue Guidance

9.507-23seekingalpha

NovoCure Q2 Earnings Exceed Expectations

7.007-14Globenewswire

NovoCure Under Investigation for Securities Fraud Claims

Show More News

NVCR Events

10/28 07:30

Novocure Collaborates with Verastem for Clinical Trial

Novocure announced that it has entered into a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate the use of Novocure's Tumor Treating Fields therapy with chemotherapy and VS-7375, Verastem's investigational oral, potent and selective KRAS G12D inhibitor, to treat locally advanced pancreatic cancer. Novocure plans to initiate a clinical trial to evaluate the safety and tolerability of TTFields therapy concomitant with gemcitabine, nab-paclitaxel, and VS-7375 in approximately 25 patients with locally advanced pancreatic cancer. Preliminary efficacy is planned to be evaluated as exploratory endpoints. Under the terms of the agreement, Novocure will manage and fund the clinical trial operations and Verastem will supply VS-7375 for the planned clinical trial. The trial is expected to begin enrolling patients in 2027.

10/1 09:30

Novocure's Optune Pax Approved in Japan for Pancreatic Cancer Treatment

Novocure announced that Japan's Ministry of Health, Labour and Welfare approved Optune Pax for the treatment of adult patients diagnosed with unresectable locally advanced pancreatic cancer, concomitant with gemcitabine and nab-paclitaxel. Optune Pax is a portable medical device that delivers Tumor Treating Fields non-invasively through wearable arrays. TTFields are alternating electric fields that disrupt processes critical for cancer cell division and survival, resulting in cancer cell death without significantly affecting healthy cells. The MHLW approval of Optune Pax was based on the results of the Phase 3 PANOVA-3 trial.

9/1 07:30

Novocure Discloses Cybersecurity Incident

In a regulatory filing, Novocure stated: "In mid-August 2026, NovoCure Limited through a subsidiary, became aware of unauthorized access to some of its information systems. Upon detecting the unauthorized access, the Company activated its cybersecurity response plan, implemented containment measures, and initiated an internal investigation of the event. The Company also engaged independent cybersecurity forensic experts to assist with the investigation, including reviewing the exposed data that was accessed. Based on the investigation to date, the Company determined that the exposed data included: internal Company patient ID numbers for over 1,400 U.S. patient records (these ID numbers are only used internally and no patient names or other identifying data for these was exposed); patient data for fewer than 50 other patients in the western U.S. that included additional identifying information; general contact information for healthcare providers we work with; and general contact information for Novocure employees, such as their job titles and phone numbers. No access to any of our medical treatment devices was obtained, our ability to operate has not been compromised and all of our systems are fully functional. The Company takes its obligation to safeguard privacy and security of its patients' data very seriously. The Company continues to evaluate applicable regulatory and legal notification requirements and will make all required notifications based on its findings, including to impacted patients. At this time, we do not believe that this cybersecurity incident will have a material impact or reasonably likely material impact on our financial condition and results of operations; however, at the time of this filing we are continuing to ascertain additional information regarding this incident. If additional information is obtained whereby we determine this cybersecurity incident will have a material impact or reasonably likely material impact on our financial condition and results of operations, we undertake to file an amendment to this Form 8-K filing under Item 1.05 containing such information within four business days after we, without unreasonable delay, determine such information, or within four business days after such information becomes available."

7/23 17:00

Stocks Decline Amid Deteriorating Macroeconomic Conditions

Stocks extended losses on Thursday amid a deteriorating macroeconomic backdrop and fresh AI worries, with concerns over accelerating artificial intelligence spending outweighing otherwise solid quarterly results. Meanwhile, rising Treasury yields and oil prices added pressure to equity markets.Oil prices jumped after Yemen's Iran-backed Houthi militant group claimed attacks on two Saudi Arabian tankers in the Red Sea, fueling worries about further conflict in the Middle East. U.S. President Donald Trump has threatened to bomb Iran infrastructure following the event and said he is seriously considering restarting major combat operations in Iran, including a "massive attack" that would be bigger than the ones previously carried out.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Alphabetreported, but slid after it also raised its FY26 capex guidanceTeslareportedand maintained its FY26 capex guidanceIBMreportedand cut its FY26 revenue growth outlook amid weakness in infrastructure revenueLockheed Martinprovided areport for Q2AMDand Cerebras Systemsannounced a partnership over a2. WALL STREET CALLS:AT&Tto Outperform at Wolfe ResearchNorwegian Cruise Lineto Hold at TruistVerisk Analyticsto Buy at JefferiesPegasystemsat KeyBanc, William Blair and Loop CapitalCitiAgilon Healthto Sell on "too rich" valuation3. AROUND THE WEB:Atari has inked a film deal with Comcast'sUniversal Pictures to develop 10 classic Atari IP for the big screen, Deadline reportsUberhas cut 10% of jobs within its customer service operations to simplify its ranks and "embrace artificial intelligence," a spokesperson confirmed to BloombergInteland Advanced Micro Devicesare signing longer-term purchase commitments with Chinese server customers for data-center processors, a consequence of the AI boom driving demand and giving suppliers leverage to seek long-term purchase deals, Reuters reportsSamsungmay invest up to EUR 1B in Mistral as part of a broader round valuing it at EUR 20B, after previously backing the AI startup through its venture arm, FT saysAmazonis being probed by the Senate Small Business Committee for allegedly allowing China to influence the ecommerce giant's online marketplace, Bloomberg reports4. MOVERS:Novocuregained in New York afterand raising its guidance for FY26Cleveland-Cliffsincreased after, providing guidance for Q3 and 2H, and providing updates on USW and POSCOPalisade Biowas higher after Oppenheimercoverage of the stock with an Outperform ratingAlbertsonswas lower after, cutting its guidance for FY26, and announcing the retirement of CFO McCollamSTMicroelectronicsfell in New York afterand providing guidance for Q35. EARNINGS/GUIDANCE:Union Pacific, with EPS and revenue beating consensusVita Cocoand raised its guidance for FY26American Airlinesand provided guidance for Q3Nasdaqand raised its guidance for FY26, with CEO Adena Friedman calling it "an outstanding second quarter"Imax, with EPS and revenue beating consensusINDEXES:The Dow fell 506.93, or 0.97%, to 51,711.65, the Nasdaq lost 533.21, or 2.15%, to 25,137.69, and the S&P 500 declined 90.66, or 1.21%, to 7,408.30.

7/23 12:30

Major Averages Drop Sharply Amid AI Spending Concerns

The major averages were sharply lower near noon as investors digest the first wave of megacap technology earnings, with concerns over accelerating artificial intelligence spending outweighing otherwise solid quarterly results. Meanwhile, Treasury yields and oil prices are climbing, adding pressure to equity markets.Oil prices are surging after Yemen's Iran-backed Houthi militant group claimed attacks on two Saudi Arabian tankers in the Red Sea, fueling worries about further conflict in the Middle East. U.S. President Donald Trump has threatened to bomb Iran infrastructure following the event and said he is seriously considering restarting major combat operations in Iran, including a "massive attack" that would be bigger than the ones previously carried out.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Alphabetreported, but slid after it also raised its FY26 capex guidanceTeslareportedand maintained its FY26 capex guidanceIBMreportedand cut its FY26 revenue growth outlook amid weakness in infrastructure revenueCSXreported better-than-expectedLockheed Martinprovided areport for Q22. WALL STREET CALLS:AT&Tto Outperform at Wolfe ResearchNorwegian Cruise Lineto Hold at TruistVerisk Analyticsto Buy at JefferiesPegasystemsat KeyBanc, William Blair and Loop CapitalCitiAgilon Healthto Sell on "too rich" valuation3. AROUND THE WEB:Yelpis expanding its role in AI-powered local search by licensing reviews, photos, and business data to OpenAI, Axios saysUberhas cut 10% of jobs within its customer service operations to simplify its ranks and "embrace artificial intelligence," a spokesperson confirmed to BloombergInteland Advanced Micro Devicesare signing longer-term purchase commitments with Chinese server customers for data-center processors, a consequence of the AI boom driving demand and giving suppliers leverage to seek long-term purchase deals, Reuters reportsSamsungmay invest up to EUR 1B in Mistral as part of a broader round valuing it at EUR 20B, after previously backing the AI startup through its venture arm, FT saysAmazonis being probed by the Senate Small Business Committee for allegedly allowing China to influence the ecommerce giant's online marketplace, Bloomberg reports4. MOVERS:Novocuregains in New York afterand raising its guidance for FY26Cleveland-Cliffsincreases after, providing guidance for Q3 and 2H, and providing updates on USW and POSCOPalisade Biohigher after Oppenheimerof the stock with an Outperform ratingAlbertsonslower after, cutting its guidance for FY26, and announcing the retirement of CFO McCollamSTMicroelectronicsfalls in New York afterand providing guidance for Q35. EARNINGS/GUIDANCE:Union Pacific, with EPS and revenue beating consensusVita Cocoand raised its guidance for FY26American Airlinesand provided guidance for Q3Nasdaqand raised its guidance for FY26, with CEO Adena Friedman calling it "an outstanding second quarter"Imax, with EPS and revenue beating consensusINDEXES:Near midday, the Dow was down 0.96%, or 502.97, to 51,715.61, the Nasdaq was down 2.22%, or 571.25, to 25,119.66, and the S&P 500 was down 1.24%, or 92.82, to 7,406.14.

Show More Events

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.